Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Zirdu who wrote (870)	6/27/1997 5:03:00 PM
From: Biomaven	of 6136

This is an interesting post from RRaney, but it overlooks one of DavidS' strong points - namely that we don't know what the "half-life" of Viracept is going to be. It's one thing to have a billion dollar drug that has ten years of life ahead of it, it's quite another to have one with just a few years life. So will Viracept still be an important drug five years from now? Ten years from now? What this means is that you have to be very careful in assuming that Agouron is going to get a similar market cap. / sales ratio to Amgen. Personally, I sold my (small) stake in Agouron a few days ago around $90, to add to my SEPR holdings, but would buy it back on any further weakness. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next